Loading clinical trials...
Loading clinical trials...
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma
Conditions
Interventions
Orelabrutinib tablet
Lenalidomide
Start Date
September 1, 2021
Primary Completion Date
September 30, 2022
Completion Date
September 30, 2023
Last Updated
August 27, 2021
NCT05139017
NCT06026319
NCT05442515
NCT01804686
NCT05755087
NCT06045247
Lead Sponsor
Puyang Oilfield General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions